Oa

Xintela (XINT): Initiation - Advancing integrins as innovation engine

Retrieved on: 
Tuesday, July 13, 2021
Cancer, Branches of biology, Biology, Breast cancer, Triple-negative breast cancer, Glioblastoma, Thomas Edison, Osteoarthritis, Biomarker, Oa

Xintela, backed by its integrin biomarker technology platform XINMARK, is a potential disrupter in the regenerative stem cell and oncology areas.

Key Points: 
  • Xintela, backed by its integrin biomarker technology platform XINMARK, is a potential disrupter in the regenerative stem cell and oncology areas.
  • Initial targets are osteoarthritis (OA), glioblastoma (GBM) and triple negative breast cancer (TNBC), all areas with significant unmet need.
  • 2021 could be a transformational year with an expected start for a Phase I/IIa trial for OA and the planned spinoff of the oncology arm.
  • About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors.

DYOPATH Wins Three Awards at the 2020 Lantern Awards

Retrieved on: 
Thursday, December 3, 2020
Telecommunications, Software, Internet, Hardware, Data management, Technology, Mobile, Wireless, Security, Business marketing, Business-to-business, Oa, Automated external defibrillator

DYOPATH, an industry leading Managed Service Provider (MSP), is excited to announce that on November 19, 2020, their new www.DYOPATH.com website and new Why Clients Choose DYOPATH animated video were given awards at the ANA Business Marketings Houston Chapter 2020 Lantern Awards.

Key Points: 
  • DYOPATH, an industry leading Managed Service Provider (MSP), is excited to announce that on November 19, 2020, their new www.DYOPATH.com website and new Why Clients Choose DYOPATH animated video were given awards at the ANA Business Marketings Houston Chapter 2020 Lantern Awards.
  • DYOPATH also won the coveted Peoples Choice Lantern Awards.
  • The Houston ANA (formerly BMA) created the Lantern Awards of Texas 32 years ago to showcase the years finest B2B marketing work.
  • DYOPATH winning at the 2020 Lantern Awards is a testimony to the consistency and caliber of work that I see from our marketing team every day.

Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting

Retrieved on: 
Tuesday, May 5, 2020
Medicine, Medical specialties, Health, Arthritis, Skeletal disorders, Medical terminology, Osteoarthritis, RTT, Osteochondritis dissecans, Inflammation, Disease, Oa

The abstracts were published in the May supplement of Molecular Therapy .

Key Points: 
  • The abstracts were published in the May supplement of Molecular Therapy .
  • By persistently suppressing inflammation, Flexion believes FX201 holds the potential to both reduce OA pain and modify the disease.
  • OA, also known as degenerative joint disease, affects more than 30 million Americans and accounts for more than $185 billion in annual expenditures.
  • We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Osteoarthritis Action Alliance Announces Launch- A National Public Health Agenda for Osteoarthritis: 2020 Update

Retrieved on: 
Monday, May 4, 2020
Skeletal disorders, RTT, Medical specialties, Medicine, Health, Arthritis, Aging-associated diseases, Rheumatology, Oa, Osteoarthritis

CHAPEL HILL, N.C., May 4, 2020 /PRNewswire/ --The Osteoarthritis Action Alliance (OAAA), in partnership with the Centers for Disease Control and Prevention (CDC) and the Arthritis Foundation (AF), have updated the National Public Health Agenda for Osteoarthritis (OA Agenda) for 2020.

Key Points: 
  • CHAPEL HILL, N.C., May 4, 2020 /PRNewswire/ --The Osteoarthritis Action Alliance (OAAA), in partnership with the Centers for Disease Control and Prevention (CDC) and the Arthritis Foundation (AF), have updated the National Public Health Agenda for Osteoarthritis (OA Agenda) for 2020.
  • OAis associated with aging, yet, over half of adults with OA, 18.7 million, are of working age (1864 years).
  • The primary audience for the 2020 OA Agenda is the public health community.
  • Overall goals of the OA Agenda 2020 update:
    Ensure the availability of evidence-based interventions to all US adults with OA.

PAINWeek 2020 Welcomes Osteoarthritis Research Society International

Retrieved on: 
Wednesday, March 25, 2020
Skeletal disorders, RTT, Medical specialties, Medicine, Health, Osteoarthritis Research Society International, Osteoarthritis, Aging-associated diseases, Rheumatology, Arthritis, Oa

MONTCLAIR, N.J., March 25, 2020 /PRNewswire-PRWeb/ --PAINWeek is pleased to announce that the Osteoarthritis Research Society International (OARSI)for the first timewill present a full day track at the PAINWeek National Conference on Tuesday, September 9.

Key Points: 
  • MONTCLAIR, N.J., March 25, 2020 /PRNewswire-PRWeb/ --PAINWeek is pleased to announce that the Osteoarthritis Research Society International (OARSI)for the first timewill present a full day track at the PAINWeek National Conference on Tuesday, September 9.
  • The Osteoarthritis Research Society International (OARSI) is the leading medical society for advancing the understanding, early detection, treatment, and prevention of osteoarthritis (OA) through its exclusive dedication to research.
  • Debra Weiner, Executive Vice President, Program Development, remarked, "Given the emergence of new guidelines and therapeutic interventions for osteoarthritis, it is very timely and relevant for OARSI to be at PAINWeek 2020."
  • OARSI is very excited to start a new collaboration with PAINWeek and jointly highlight the exciting research and new treatment guidelines that are being developed.

Bioventus Launches DUROLANE® SJ (1mL) in Australia and New Zealand; Receives Expanded Indications for DUROLANE (3mL)

Retrieved on: 
Monday, August 12, 2019
Biotechnology, Managed care, General Health, Health, Medical devices, Research, Surgery, Science, Skeletal disorders, RTT, Medicine, Medical specialties, Organ systems, Arthritis, Osteoarthritis, Aging-associated diseases, Rheumatology, Oa, Pain, LMT Surgical, Bioventus

Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE SJ (1mL), and has received expanded indications for DUROLANE (3mL), its single-injection joint-fluid osteoarthritis (OA) treatment, in Australia and New Zealand.

Key Points: 
  • Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE SJ (1mL), and has received expanded indications for DUROLANE (3mL), its single-injection joint-fluid osteoarthritis (OA) treatment, in Australia and New Zealand.
  • More than two million Australian citizens suffer from some form of osteoarthritis,1 said John Nosenzo, Chief Commercial Officer, Bioventus.
  • The availability of DUROLANE SJ, and the expanded indications for DUROLANE, gives them, and OA patients in New Zealand, even more options for OA pain relief.
  • We are excited to work with Bioventus and introduce both DUROLANE and DUROLANE SJ to more patients seeking OA pain relief, said Kerry Lawford, Managing Director, LMT Surgical.

OA Experiential Launches "Immersive Core" Giving Brands Access To Some Of The Best Immersive Creators In The U.S.

Retrieved on: 
Wednesday, May 8, 2019
Oa

LOS ANGELES, May 8, 2019 /PRNewswire/ -- OA Experiential, a creative and production agency, has launched a new initiative called the "OA Immersive Core."

Key Points: 
  • LOS ANGELES, May 8, 2019 /PRNewswire/ -- OA Experiential, a creative and production agency, has launched a new initiative called the "OA Immersive Core."
  • Collectively, OA's Core has created world-renowned experiential and site-specific immersions, award-winning escape rooms, innovative single-guest experiences, and trans-media creations.
  • OA Experiential( oaexp.com ) is a full-service creative, design and production agency specializing in high-quality, high-visibility brand activations and immersive experiences.
  • OA Experiential won Event Marketer's Best Outdoor Environment of 2018 for their design and production of NBC's The Good Place at ComicCon.

Goal Zero Adds New Portable Solar Panel and Updated Power Banks to Popular Product Lines at CES 2019

Retrieved on: 
Tuesday, January 8, 2019
Electric battery, Electric power, Kenji Uedo, Oa

SALT LAKE CITY, Jan. 8, 2019 /PRNewswire/ -- Goal Zero, the leader in portable power, introduced new products toits battery and portable charging categories.

Key Points: 
  • SALT LAKE CITY, Jan. 8, 2019 /PRNewswire/ -- Goal Zero, the leader in portable power, introduced new products toits battery and portable charging categories.
  • "Powering anything, anywhere has been Goal Zero's mantra since the beginning," said Bill Harmon, general manager at Goal Zero.
  • "The introduction of the new Nomad 5 and more powerful Flip Power Banks give people additional options to have endless power wherever life takes them."
  • Power.